Renforth Resources Inc., a Canadian junior gold exploration company, will participate in the 3rd Annual ArcStone Kingswood Growth Summit in Toronto on September 16, 2026. Nicole Brewster, the company's President and CEO, will engage in one-on-one meetings with investors and capital market professionals. The summit gathers growth issuers and investors for presentations, networking, and discussions on industry developments. This event offers Renforth an opportunity to showcase its projects, including the Parbec gold deposit and Victoria polymetallic deposit, to potential investors and partners.
Renforth Resources is attending the ArcStone Kingswood Growth Summit 2026 in Toronto. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 15, 2026 21:43 WIB: of 32 priced US Basic Materials stocks, 10 rose and 22 fell. Notable prices include SLI at USD 2.04 (-2.39%), EXK at USD 9.51 (-2.16%), and LYB at USD 64.10 (+2.14%).
In Q3 2026, websites on Cloudflare's network blocked 13.47% of AI crawler requests, more than double the 5.98% blocked a year earlier. This rise in access denial affects how brands appear in AI-generated answers from platforms like ChatGPT, Gemini, a...
JPMorgan Asset Management (Canada) announced the final cash distributions for September 2026 for three of its ETFs traded on the Toronto Stock Exchange. Unitholders of record on October 19, 2026, will receive payments on October 23, 2026. The ETFs an...
Stillwater Critical Minerals Corp. has upgraded to the OTCQX Best Market from the OTCQB Venture Market, beginning trading under the symbol "PGEZF." This move enhances the company's visibility, liquidity, and accessibility to U.S. investors as it adva...
WasabiCard, a stablecoin-based global payment provider, engaged in key partnership discussions at TOKEN2049 Singapore 2026, focusing on white-label card issuing, global payouts, and embedded payments. The company highlighted growing demand in APAC fo...
The global next generation antibody therapeutics market is projected to increase from $5.45 billion in 2026 to $5.76 billion by 2035, growing at a CAGR of 1%. Growth is fueled by advances in biotechnology, rising demand for targeted therapies, and in...
